Last updated on November 2018

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Brief description of study

Primary Objective:

To demonstrate the superiority of sotagliflozin 400 mg versus placebo on Hemoglobin A1c (HbA1c) reduction at Week 26 in patients with type 2 diabetes (T2D) who have inadequate glycemic control with a sulfonylurea alone or in combination with metformin.

Secondary Objectives:

  • To compare sotagliflozin 400 mg versus placebo based on:
  • Change from baseline in fasting plasma glucose (FPG).
  • Change from baseline in systolic blood pressure (SBP) for patients with baseline SBP 130 mm Hg.
  • Change from baseline in SBP for all patients.
  • Change from baseline in body weight.
  • Proportion of patients with HbA1c <6.5% and <7.0%.
  • To evaluate the safety of sotagliflozin 400 mg versus placebo throughout the 79-week trial.

Detailed Study Description

The duration per patient is up to 85 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks and a 2-week single-blind Run-in phase, a 26-week double blind Core Treatment Period, a 53 week double blind Extension, and a 2-week post treatment Follow-up period to collect safety information.

Clinical Study Identifier: NCT03066830

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 7033003
Sturovo, Slovakia

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.